<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03062826</url>
  </required_header>
  <id_info>
    <org_study_id>HMUOCT-EROSIONⅡ</org_study_id>
    <nct_id>NCT03062826</nct_id>
  </id_info>
  <brief_title>EROSION II: OCT Guided PPCI in STEMI</brief_title>
  <official_title>A Prospective，Multicenter，Optical Coherence Tomography Guided Reperfusion Strategy in Patients With STEMI（EROSION II）</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Harbin Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol describes a perspective,multicenter study intended to test the hypothesis that
      patients with STEMI caused by plaque rupture or plaque erosion without obstructive stenosis
      (diameter stenosis &lt;70%) can be stabilized by effective antithrombotic treatment without
      stent implantation, thereby avoiding both early and late complications related to
      percutaneous coronary intervention (PCI).

      Patients with STEMI within 12 hours will be included for screening. Thrombus aspiration will
      be performed in patients with large thrombus burden and TIMI flow grade less than 2 to
      restore blood flow. OCT will be used to assess the underlying mechanism including plaque
      rupture, erosion, calcified nodule, and other uncommon reasons.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of thrombus burden assessed by OCT</measure>
    <time_frame>30 days</time_frame>
    <description>The efficacy will be assessed by 50% reduction in thrombus burden by OCT at 1 month.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major cardiovascular adverse events</measure>
    <time_frame>1, 3, 6, 9，12 months after PCI</time_frame>
    <description>In patients treated conservatively, the safety objectives are to evaluate the occurrence of any adverse events during 1, 3, 6, 9，12 months follow up (re-infarction, re-hospitalization, revascularization by PCI or CABG, cardiac death, stoke, and major bleeding).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major cardiovascular adverse events</measure>
    <time_frame>1 and 12 months after PCI</time_frame>
    <description>compare the difference of clinical outcome in patients with plaque rupture and erosion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective flow area</measure>
    <time_frame>1 and 12 months after PCI</time_frame>
    <description>Effective flow area increase</description>
  </secondary_outcome>
  <enrollment type="Anticipated">340</enrollment>
  <condition>STEMI - ST Elevation Myocardial Infarction</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Study population is STEMI patients who undergo primary cardiac catheterization.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or non-pregnant women &gt;18 years of age and &lt; 75 years of age

          -  Patients undergo cardiac catheterization for STEMI. STEMI will be defined as
             continuous chest pain for &gt;30 minutes, arrival at the hospital within 24 hours from
             chest pain onset, ST-segment elevation &gt;0.1 mV in at least two contiguous leads, or
             new left bundle-branch block on the 12-lead electrocardiogram (ECG), and elevated
             cardiac markers (troponin T/I or creatine kinase-MB).

          -  Culprit lesion located in a native coronary artery

          -  TIMI flow grade 3 and diameter stenosis &lt; 70% on angiogram or MLA＞1.6mm2；

          -  Definite erosion and rupture defined by OCT

          -  Patients able to provide written informed consent

        Exclusion Criteria:

          -  Left ventricular ejection fraction &lt; 30%.

          -  Lesions on LM, ostial LAD.

          -  Long lesions, circuity lesion and angulation lesions

          -  more than 2 severe lesions

          -  Massive residual thrombosis after the thrombus aspiration.

          -  With the history of cardiopulmonary resuscitation (CPR), acute pulmonary edema and
             cardiac shock on the attacks.

          -  Life expectancy &lt; 1 year.

          -  Contraindication to the contrast media.

          -  Creatinine level &gt; 2.0 mg/dL or end-stage kidney disease.

          -  Serious liver dysfunction.

          -  Patients with hemodynamic or electrical instability (including shock).

          -  Any contraindication against the use of ticagrelor.

          -  Investigator considers the patient is not suitable.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo YU, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Second Affiliated Hospital of Harbin Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bo YU, MD,PhD</last_name>
    <email>yubodr@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing An Zhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zening Jin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Chao-Yang Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lefeng Wang</last_name>
      <email>wlf311@sohu.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qiang Xie</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Daqing Oilfield General Hospital</name>
      <address>
        <city>Daqing</city>
        <state>Heilongjiang</state>
        <zip>163001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hui Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Yu, MD,PhD</last_name>
      <phone>86-045186605180</phone>
      <email>yubodr@163.com</email>
    </contact>
    <investigator>
      <last_name>Bo Yu, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yanqing Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yang Zheng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bin Liu</last_name>
      <email>liubin3333@vip.sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The third hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ping Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi'an Jiao Tong University</name>
      <address>
        <city>Xi'an Shi</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zuyi Yuan</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2017</study_first_submitted>
  <study_first_submitted_qc>February 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Harbin Medical University</investigator_affiliation>
    <investigator_full_name>Yu Bo</investigator_full_name>
    <investigator_title>The Second Affiliated Hospital of Harbin Medical University</investigator_title>
  </responsible_party>
  <keyword>OCT</keyword>
  <keyword>STEMI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

